A Cell‐free DNA Barcode‐Enabled Single‐Molecule Test for Noninvasive Prenatal Diagnosis of Monogenic Disorders: Application to β‐Thalassemia
Autor: | Xingkun Yang, Qinghua Zhou, Wanjun Zhou, Mei Zhong, Xiaoling Guo, Xiaofeng Wang, Xin Fan, Shanhuo Yan, Liyan Li, Yunli Lai, Yongli Wang, Jin Huang, Yuhua Ye, Huaping Zeng, Jun Chuan, Yuanping Du, Chouxian Ma, Peining Li, Zhuo Song, Xiangmin Xu |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: | |
Zdroj: | Advanced Science, Vol 6, Iss 11, Pp n/a-n/a (2019) |
Druh dokumentu: | article |
ISSN: | 2198-3844 20180233 |
DOI: | 10.1002/advs.201802332 |
Popis: | Abstract Noninvasive prenatal testing of common aneuploidies has become routine over the past decade, but testing of monogenic disorders remains a challenge in clinical implementation. Most recent studies have inherent limitations, such as complicated procedures, a lack of versatility, and the need for prior knowledge of parental genotypes or haplotypes. To overcome these limitations, a robust and versatile next‐generation sequencing‐based cell‐free DNA (cfDNA) allelic molecule counting system termed cfDNA barcode‐enabled single‐molecule test (cfBEST) is developed for the noninvasive prenatal diagnosis (NIPD) of monogenic disorders. The accuracy of cfBEST is found to be comparable to that of droplet digital polymerase chain reaction (ddPCR) in detecting low‐abundance mutations in cfDNA. The analytical validity of cfBEST is evidenced by a β‐thalassemia assay, in which a blind validation study of 143 at‐risk pregnancies reveals a sensitivity of 99.19% and a specificity of 99.92% on allele detection. Because the validated cfBEST method can be used to detect maternal‐fetal genotype combinations in cfDNA precisely and quantitatively, it holds the potential for the NIPD of human monogenic disorders. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |